Etomidate Versus Ketamine for Emergency Intubation in Critically Ill Patients: An Updated Meta-Analysis and Systematic Review

This updated meta-analysis of six randomized controlled trials involving over 4,000 critically ill patients found no significant difference in 28-day mortality between etomidate and ketamine for emergency intubation, though ketamine was associated with a higher incidence of post-intubation hypotension.

The Gist

Imagine you are the captain of a ship (the patient) that is taking on water and is in danger of sinking. You need to quickly secure the airway to keep the ship afloat, but the process of doing so (intubation) is like hitting a "reset button" that can cause the ship's engines to sputter or stop completely.

To prevent this, doctors use powerful "sedative anchors" to knock the patient out before the procedure. For years, there has been a fierce debate in the medical world about which anchor is better: Etomidate or Ketamine.

Here is the story of a new study that finally settled the argument, explained simply.

The Two Contenders

1. Etomidate (The Steady Hand):

   • The Reputation: For a long time, Etomidate was the "gold standard" for sick patients. It's known for being very gentle on the heart and blood pressure. It's like a calm, steady anchor that doesn't shake the ship.
   • The Scandal: However, there was a dark secret. Etomidate temporarily shuts down the body's "stress factory" (the adrenal glands). Doctors worried that for patients already fighting a massive infection (sepsis), turning off this factory might kill them. It was like taking away the ship's emergency generator right when it's needed most.

2. Ketamine (The Energy Booster):

   • The Reputation: Ketamine is the "rev-up" drug. It stimulates the nervous system, theoretically keeping blood pressure high and the heart pumping hard. It was the go-to choice for patients in shock, like a turbocharger for a dying engine.
   • The Risk: But recently, doctors started wondering if this turbocharger was too much for a broken engine. In patients who are already exhausted and have run out of their own "fighting chemicals" (catecholamines), Ketamine might actually cause the engine to stall completely.

The Big Race (The Study)

The authors of this paper decided to stop guessing and start counting. They gathered six massive, high-quality experiments (involving over 4,000 patients) where doctors were forced to flip a coin to decide which drug to use. This removed all the guessing and bias.

They looked at two main things:

1. Did the patient survive for 28 days? (The ultimate test).
2. Did the patient's blood pressure crash after the procedure? (The immediate safety test).

The Results: What Did the Data Say?

1. The Survival Race: A Dead Heat 🏁
The big question was: Does Etomidate's "stress factory shutdown" actually kill more people?

• The Answer: No.
• The Analogy: It turned out that the "stress factory" shuts down for a few hours, but the body is so good at recovering that it doesn't matter for the final outcome. Whether you used the "Steady Hand" (Etomidate) or the "Energy Booster" (Ketamine), the number of patients who survived 28 days was almost exactly the same (about 40% in both groups). The "scandal" of Etomidate didn't actually lead to more deaths.

2. The Blood Pressure Crash: Ketamine Stumbles 📉
The second question was: Is Ketamine safer for blood pressure?

• The Answer: Actually, no.
• The Analogy: Doctors thought Ketamine was the "turbocharger" that would keep the engine running. But in these very sick patients, the "turbo" didn't work. Instead, Ketamine acted more like a heavy weight on the engine, causing the blood pressure to drop more often than Etomidate did.
  • The Stats: About 14 out of 100 patients on Ketamine had a blood pressure crash, compared to only 11 out of 100 on Etomidate. While that sounds small, in a hospital, it means Etomidate is actually the safer bet for keeping blood pressure stable.

3. The Other Stuff

• Did one drug make intubation easier? No.
• Did one drug cause more heart stops? No.
• Did one drug get patients out of the ICU faster? No.

The Bottom Line

For a long time, doctors were terrified of Etomidate because of the "adrenal shutdown" theory, and they loved Ketamine because they thought it was a "blood pressure savior."

This study flips the script:

• Etomidate is safe. The fear that it kills septic patients was unfounded. It keeps blood pressure very stable.
• Ketamine is not the magic bullet for low blood pressure. In fact, it might make low blood pressure worse in the sickest patients.

The Takeaway for the Captain:
If you are the doctor standing over a critically ill patient, you don't have to panic about choosing the "perfect" drug based on fear of death. Both drugs get the job done equally well regarding survival. However, if you are worried about the patient's blood pressure dropping during the procedure, Etomidate is currently the more reliable choice.

The choice isn't about which one is "better" for everyone; it's about knowing that Etomidate is the steady anchor, and Ketamine isn't the miracle turbocharger we thought it was.

Technical Summary

1. Problem Statement

Rapid Sequence Intubation (RSI) is a high-risk procedure for critically ill patients, carrying significant risks of life-threatening complications such as severe hypotension and cardiac arrest. The choice of induction agent is critical.

• Etomidate: Traditionally favored for hemodynamic stability but associated with transient adrenal suppression (inhibition of 11β-hydroxylase), raising concerns about increased mortality in septic patients.
• Ketamine: A dissociative anesthetic with sympathomimetic properties, theoretically preferred for shock states to maintain blood pressure. However, recent evidence suggests it may cause cardiovascular collapse in patients with depleted catecholamine reserves ("catecholamine washout").

Current clinical guidelines lack a definitive recommendation due to conflicting evidence, particularly from older studies limited by observational data, small sample sizes, or heterogeneity. This study aims to resolve the debate using high-quality data from recent large-scale Randomized Controlled Trials (RCTs).

2. Methodology

• Study Design: Systematic review and meta-analysis of RCTs, adhering to PRISMA guidelines and the Cochrane Handbook.
• Data Sources: PubMed, Embase, and the Cochrane Library (searched from inception to January 2026), plus manual screening of reference lists.
• Eligibility Criteria:
  • Population: Critically ill adults (≥18 years) requiring emergency RSI in non-operating room settings (ED/ICU).
  • Intervention: Single-dose IV Ketamine vs. Etomidate.
  • Exclusions: Observational studies, pregnant patients, prisoners, and patients in cardiac arrest prior to intubation.
• Data Synthesis:
  • Included Studies: 6 RCTs comprising 4,108 patients (2,046 Ketamine; 2,062 Etomidate).
  • Statistical Model: Restricted Maximum Likelihood random-effects model.
  • Outcomes: Primary outcome was 28-day all-cause mortality. Secondary outcomes included post-intubation hypotension, peri-intubation cardiac arrest, first-attempt success, and resource utilization (ICU/ventilator-free days).
  • Subgroup Analysis: Prespecified analysis for patients with sepsis.
  • Quality Assessment: Risk of bias assessed via RoB 2 tool; certainty of evidence graded via GRADE framework.

3. Key Contributions

• Updated Evidence Base: This is the first meta-analysis to incorporate the most recent large-scale multicenter RCTs (published up to 2026), providing a larger sample size (N=4,108) than previous reviews.
• Sepsis-Specific Analysis: It specifically addresses the long-standing controversy regarding etomidate's safety in septic patients, a population where the theoretical risk of adrenal suppression is most debated.
• Hemodynamic Re-evaluation: It challenges the traditional dogma that ketamine is universally superior for hemodynamic stability in shock states, providing robust data on post-intubation hypotension.
• Methodological Rigor: By restricting inclusion to RCTs and excluding observational data, the study minimizes confounding variables common in previous meta-analyses.

4. Results

Primary Outcome: 28-Day Mortality

• Overall: No statistically significant difference between Ketamine (39.0%) and Etomidate (40.3%).
  • Relative Risk (RR): 0.96 (95% CI, 0.89–1.03; p=0.29).
  • Heterogeneity: Low (I² = 11%).
• Sepsis Subgroup: In patients with sepsis (n=1,546), mortality remained comparable (Ketamine 46.0% vs. Etomidate 47.0%).
  • RR: 0.94 (95% CI, 0.86–1.03; p=0.20).
  • No significant interaction between sepsis status and treatment effect.

Secondary Outcomes

• Post-Intubation Hypotension: Ketamine was associated with a statistically significant increase in risk compared to Etomidate.
  • Incidence: 14.2% (Ketamine) vs. 11.3% (Etomidate).
  • RR: 1.25 (95% CI, 1.01–1.53; p=0.04).
  • Heterogeneity: 0%.
• Peri-Intubation Cardiac Arrest: No significant difference (1.9% vs. 1.7%; RR 1.13; p=0.60).
• Procedural Efficacy: First-attempt intubation success was similar (87.1% vs. 87.6%; p=0.76).
• Resource Utilization: No significant differences in ICU-free days or ventilator-free days.

Quality of Evidence

• The certainty of evidence for mortality and hypotension was rated as High using the GRADE framework.
• Sensitivity analysis including an unpublished quasi-randomized trial did not alter the primary findings.

5. Significance and Clinical Implications

• Resolution of Mortality Debate: The study definitively demonstrates that single-dose etomidate does not increase 28-day mortality in critically ill patients, including those with sepsis. This alleviates concerns regarding "pharmacologic adrenalectomy" affecting survival outcomes in the acute setting.
• Reassessment of Ketamine: Contrary to the belief that ketamine is the safest agent for hemodynamically unstable patients, this study shows it carries a higher risk of post-intubation hypotension. This supports the "catecholamine depletion" hypothesis, where ketamine's direct negative inotropic effects may unmask in patients with profound shock.
• Clinical Practice: The choice of induction agent should be individualized. While both agents are viable, clinicians should exercise caution with ketamine in patients at high risk for hemodynamic collapse, as etomidate appears to offer a more favorable hemodynamic safety profile regarding hypotension, despite its known adrenal effects.
• Future Directions: The authors suggest exploring alternative strategies, such as "ketofol" (ketamine/propofol admixtures) or adjuvant therapies, to mitigate the specific hemodynamic risks of single-agent induction in high-risk subgroups.